Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03288662
Other study ID # LAnh
Secondary ID
Status Completed
Phase N/A
First received September 7, 2017
Last updated September 19, 2017
Start date October 1, 2013
Est. completion date July 31, 2017

Study information

Verified date September 2017
Source Military Hospital 103
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

the World Health Organization (WHO) has proposed a classification of histopathological thymic tumor and it significance in prognosis. Chest computed tomography (CT) is the most common method to evaluate thymic epithelial tumors before operation. Therefore, the question is to predict the histopathological type of thymic epithelial tumors before surgery based on CT-scan images , to help determine treatment strategy and prognosis. In Vietnam, there are no published literature on this issue.


Description:

1. Introduction: the World Health Organization (WHO) has proposed a classification of histopathological thymic tumor and it significance in prognosis. Chest computed tomography (CT) is the most common method to evaluate thymic epithelial tumors before operation. Therefore, the question is to predict the histopathological type of thymic epithelial tumors before surgery based on CT-scan images , to help determine treatment strategy and prognosis. In Vietnam, there are no published literature on this issue.

2. Materials and methods:

2.1. Cross-sectional descriptive study on 53 patients with diagnosed of thymoma by CT and had postoperative histopathology results as thymic epithelial tumors

2.2. Time and Place: in Departement of CTVS, Military Hospital 103, Vietnam from 10/2013 to 7/2017.

2.3. methods:

- study in chest CT scan:

- Measure the maximun diameter of the tumor

- The contour: smooth contour or irregular contour

- The shape: round, oval and plaque base on the ratio between long axis and short axis of the tumor

- Some other characteristics: Degree of enhancement, Level of drug absorbed, Calcification, Invasion the local organs and Capsular destruction.

- Histopathological study: based on the 2004 WHO classification:

- Thymoma: type A, AB, B1, B2, B3

- Thymic carcinoma

- Data processing: use software Epi Info 2000.

3. Expectation of results

- Relationship between the size and histopathological type of thymic epithelial tumors.

- Comparison of some characteristics of the tumor on preoperative chest CT scans and histopathological type of thymic epithelial tumors


Recruitment information / eligibility

Status Completed
Enrollment 2
Est. completion date July 31, 2017
Est. primary completion date July 1, 2017
Accepts healthy volunteers No
Gender All
Age group 21 Years to 71 Years
Eligibility Inclusion Criteria:

- All of patient have a chest CT scan pre-operation and a result of thymic epithelial tumors postoperative histopathology

Exclusion Criteria:

- Incomplete or loss the CT and postoperative histopathology

Study Design


Related Conditions & MeSH terms


Intervention

Other:
CT and histopathological classification
Cross-sectional descriptive study on 53 patients with diagnosed of thymoma by CT and had postoperative histopathology results as thymic epithelial tumors. Base on the characteristics in Chest CT scan in each postoperative histopathology results.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Military Hospital 103 Nguyen Truong Giang

Outcome

Type Measure Description Time frame Safety issue
Primary maximun diameter of the tumor Measure the maximun diameter of the tumor in chest CT scan 1 month
See also
  Status Clinical Trial Phase
Recruiting NCT01950572 - Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Terminated NCT00818090 - Paclitaxel and Cisplatin for Thymic Neoplasm Phase 2
Completed NCT00332969 - Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma Phase 2
Completed NCT00921739 - Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies Phase 1
Recruiting NCT05255965 - IL-8+ naïve T Cells as a Biomarker for Thymoma Identification
Withdrawn NCT02948855 - Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases
Completed NCT00387868 - Preoperative Treatment of Patients With High Risk Thymoma Phase 2
Completed NCT01272817 - Nonmyeloablative Allogeneic Transplant N/A
Recruiting NCT03466827 - Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma Phase 2
Completed NCT02220855 - A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas Phase 2
Active, not recruiting NCT01242072 - Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies Phase 1
Recruiting NCT06029621 - Robot-assisted vs VATS for Thymoma N/A
Active, not recruiting NCT03921671 - Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT) Phase 2
Active, not recruiting NCT01621568 - Sunitinib for Advanced Thymus Cancer Following Earlier Treatment Phase 2
Recruiting NCT05262582 - Comparison of Single Port and Two Ports Robotic Assisted Thoracic Surgery for Thymectomy N/A
Terminated NCT01100944 - A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies Phase 1/Phase 2
Active, not recruiting NCT03968315 - An Investigational Scan (MRI) in Imaging Patients With Newly-Diagnosed or Recurrent Thymoma N/A
Recruiting NCT04162691 - Single Cell Sequencing Analysis of Thymoma
Recruiting NCT06086327 - Application of 68Ga-Pentixafor PET/CT for Thymoma Early Phase 1
Completed NCT01364727 - A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Phase 2